DuPont de Nemours (NYSE:DD) Stock Price Expected to Rise, UBS Group Analyst Says

DuPont de Nemours (NYSE:DD) had its target price hoisted by equities research analysts at UBS Group from $172.00 to $182.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the basic materials company’s stock. UBS Group‘s target price suggests a potential upside of 20.41% from the company’s previous close.

Several other research analysts have also weighed in on the company. Barclays boosted their price target on DuPont de Nemours from $156.00 to $176.00 and gave the stock an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group decreased their target price on shares of DuPont de Nemours from $159.00 to $153.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. Royal Bank Of Canada lowered their target price on shares of DuPont de Nemours from $176.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, October 15th. Zacks Research lowered shares of DuPont de Nemours from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Finally, Citigroup increased their price target on shares of DuPont de Nemours from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.75.

DuPont de Nemours Stock Down 1.5%

Shares of DuPont de Nemours stock traded down $2.31 during trading hours on Wednesday, reaching $151.15. 2,547,775 shares of the company’s stock were exchanged, compared to its average volume of 1,350,642. The company has a 50 day moving average of $132.64 and a two-hundred day moving average of $138.51. DuPont de Nemours has a fifty-two week low of $111.15 and a fifty-two week high of $157.98. The company has a current ratio of 2.43, a quick ratio of 1.82 and a debt-to-equity ratio of 0.23. The stock has a market cap of $20.41 billion, a P/E ratio of 335.96, a P/E/G ratio of 1.31 and a beta of 1.06.

DuPont de Nemours (NYSE:DD) last announced its quarterly earnings data on Tuesday, November 3rd. The basic materials company reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.22. The company had revenue of $1.87 billion during the quarter, compared to analysts’ expectations of $1.84 billion. DuPont de Nemours had a return on equity of 6.92% and a net margin of 0.67%. DuPont de Nemours’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 EPS. On average, sell-side analysts forecast that DuPont de Nemours will post 7.25 EPS for the current fiscal year.

Institutional Trading of DuPont de Nemours

Several hedge funds and other institutional investors have recently modified their holdings of DD. State Street Corp boosted its holdings in shares of DuPont de Nemours by 140.3% during the second quarter. State Street Corp now owns 44,941,824 shares of the basic materials company’s stock worth $6,095,909,000 after acquiring an additional 26,238,300 shares during the period. KBC Group NV grew its position in shares of DuPont de Nemours by 435.8% in the first quarter. KBC Group NV now owns 1,687,376 shares of the basic materials company’s stock valued at $77,281,000 after purchasing an additional 1,372,435 shares during the last quarter. TD Waterhouse Canada Inc. increased its stake in shares of DuPont de Nemours by 7,762.1% during the third quarter. TD Waterhouse Canada Inc. now owns 949,117 shares of the basic materials company’s stock worth $123,281,000 after purchasing an additional 937,045 shares during the period. Bank of America Corp DE increased its stake in shares of DuPont de Nemours by 22.0% during the first quarter. Bank of America Corp DE now owns 4,629,671 shares of the basic materials company’s stock worth $212,039,000 after purchasing an additional 835,572 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in DuPont de Nemours during the 1st quarter worth approximately $34,727,000. Institutional investors own 73.96% of the company’s stock.

Key Stories Impacting DuPont de Nemours

Here are the key news stories impacting DuPont de Nemours this week:

• Positive Sentiment: DuPont beat third-quarter estimates: adjusted EPS was $2.09 versus the $1.87 consensus, while revenue of $1.87 billion topped expectations and rose 4% year over year. Organic sales increased 5%. DuPont Q3 results
• Positive Sentiment: The company raised its full-year 2026 outlook again after exceeding third-quarter guidance, citing strength in healthcare and aerospace demand. It also plans another $250 million in share repurchases in the fourth quarter. Reuters outlook report
• Positive Sentiment: Citigroup raised its target to $176 from $162 and reiterated a Buy rating; Barclays raised its target to $176 from $156 and maintained Overweight. Both targets imply about 16% upside from the quoted share price. Citigroup rating
• Neutral Sentiment: A report highlighted DuPont’s new peptide-purification product, but the available information does not quantify its potential revenue or earnings contribution. Peptide purification product report
• Negative Sentiment: Despite the favorable updates, shares are lower in Wednesday trading following Tuesday’s strong post-earnings advance. The recent articles point to no new negative company-specific development, so profit-taking may be contributing to the pullback.

DuPont de Nemours Company Profile

DuPont de Nemours, Inc is a diversified science and technology company that develops engineered materials and specialty products for industrial and consumer markets. Its offerings are used in applications including electronics, semiconductor manufacturing, water purification, transportation, construction, healthcare, and worker and consumer protection.

The company’s product portfolio has historically included high-performance films, resins, adhesives, engineered polymers, specialty fibers, protective materials, water-treatment membranes, and filtration technologies.